The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children

Vaccine

Volumn 32, Issue 37, 2014, Pages 4791-4798

  Wang, Bing ^a,b,c   Haji Ali Afzali, Hossein ^b   Marshall, Helen ^a,b,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

Inpatient costs; Length of admission; Meningococcal B vaccines; Meningococcal disease

Indexed keywords

ARTICLE; AUSTRALIA; BLOOD GROUP TYPING; CHILD; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITAL SERVICE; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MENINGOCOCCOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SEPTICEMIA; COMPLICATION; COST; ECONOMICS; EPIDEMIC MENINGITIS; HOSPITAL; HOSPITALIZATION; INFANT; MICROBIOLOGY; MULTIVARIATE ANALYSIS; NEISSERIA MENINGITIDIS; REGRESSION ANALYSIS; SEPSIS;

CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HOSPITALS, PEDIATRIC; HUMANS; INFANT; INPATIENTS; LENGTH OF STAY; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS; MULTIVARIATE ANALYSIS; NEISSERIA MENINGITIDIS, SEROGROUP B; REGRESSION ANALYSIS; SEPSIS; SOUTH AUSTRALIA;

EID: 84905235014     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.05.069     Document Type: Article

References (42)

1. Hart C.A., Thomson A.P. Meningococcal disease and its management in children. BMJ 2006, 333(7570):685-690.
2. Moore P.S. Meningococcal meningitis in sub-Saharan Africa: a model for the epidemic process. Clin Infect Dis 1992, 14(2):515-525.
3. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., Hughes J.M. Meningococcal disease. N Engl J Med 2001, 344(18):1378-1388.
4. Schuchat A., Robinson K., Wenger J.D., Harrison L.H., Farley M., Reingold A.L., et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997, 337(14):970-976.
5. Harrison L.H. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010, 50(Suppl. 2):S37-S44.
6. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl. 2):B51-B63.
7. The Australian immunisation handbook 2013, National Health Medical Research Council, Canberra.
8. Borg J., Christie D., Coen P.G., Booy R., Viner R.M. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics 2009, 123(3):e502-e509.
9. Davis K.L., Misurski D., Miller J., Karve S. Cost impact of complications in meningococcal disease: evidence from a United States managed care population. Hum Vaccines 2011, 7(4):458-465.
10. Erickson L., De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 1998, 26(5):1159-1164.
11. Karve S., Misurski D., Miller J., Davis K.L. Costs of sequelae associated with invasive meningococcal disease: findings from a US managed care population. Health Outcomes Res Med 2011, 2:e215-e226.
12. Viner R.M., Booy R., Johnson H., Edmunds W.J., Hudson L., Bedford H., et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 2012, 11(9):774-783.
13. Atkinson W. Epidemiology and prevention of vaccine-preventable diseases 2000, Dept. of Health & Human Services, Public Health Service, Centers for Disease Control and Prevention.
14. Notification rate of meningococcal disease (invasive), Australia, 2012 by age group and sex [database on the Internet] 2013, Department of Health and Ageing, Atlanta, GA, Available from: http://www9.health.gov.au/cda/source/rpt_5.cfm [accessed 23.07.13].
15. Meningococcal disease prevention and control strategies for practice-based physicians (Addendum: recommendations for college students). Committee on Infectious Diseases. Pediatrics 2000, 106(6):1500-1504.
16. Dang V., Jamieson F.B., Wilson S., Rawte P., Crowcroft N.S., Johnson K., et al. Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010. BMC Infect Dis 2012, 12:202.
17. Annual report of the Australian Meningococcal Surveillance Programme 2001. Commun Dis Intell Q Rep 2002, 26(3):407-418.
18. Lahra M.M., Enriquez R.P. Annual report of the Australian Meningococcal Surveillance Programme, 2011. Commun Dis Intell Q Rep 2012, 36(3):E251-E262.
19. ® meningococcal B vaccine in the UK 2013, Department of Health, London, Available from: https://www.gov.uk/government/publications/jcvi-interim-position-statement-on-the-use-of-bexsero-meningococcal-b-vaccine-in-the-uk [accessed 02.09.13].
20. Davis K.L., Bell T.J., Miller J.M., Misurski D.A., Bapat B. Hospital costs, length of stay and mortality associated with childhood, adolescent and young adult meningococcal disease in the US. Appl Health Econ Health Policy 2011, 9(3):197-207.
21. Davis K.L., Misurski D.A., Miller J.M., Bell T.J., Bapat B. Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the United States. Hum Vaccines 2011, 7(1):96-101.
22. O'Brien J.A., Caro J.J., Getsios D. Managing meningococcal disease in the United States: hospital case characteristics and costs by age. Value Health 2006, 9(4):236-243.
23. Robinson P.M. The epidemiology of meningococcal disease in Victoria, 1997 2002, [PhD thesis], University of Melbourne, Melbourne, Victoria.
24. Wright C., Wordsworth R., Glennie L. Counting the cost of meningococcal disease: scenarios of severe meningitis and septicemia. Paediatr Drugs 2013, 15(1):49-58.
25. Durand-Zaleski I. Why cost-of-illness studies are important and inform policy. Vasc Med 2008, 13(3):251-253.
26. Ortega-Sanchez I.R., Meltzer M.I., Shepard C., Zell E., Messonnier M.L., Bilukha O., et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis 2008, 46(1):1-13.
27. Scott R.D., Meltzer M.I., Erickson L.J., De Wals P., Rosenstein N.E. Vaccinating first-year college students living in dormitories for meningococcal disease: an economic analysis. Am J Prev Med 2002, 23(2):98-105.
28. Shepard C.W., Ortega-Sanchez I.R., Scott R.D., Rosenstein N.E., Team A.B. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 2005, 115(5):1220-1232.
29. Skull S.A., Butler J.R. Meningococcal vaccination for adolescents? An economic evaluation in Victoria. J Paediatr Child Health 2001, 37(5):S28-S33.
30. Trotter C.L., Edmunds W.J. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ 2002, 324(7341):809.
31. Trotter C.L., Edmunds W.J. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Mak 2006, 26(1):38-47.
32. Christensen H., Hickman M., Edmunds W.J., Trotter C.L. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 2013, 31(23):2638-2646.
33. Miller M.A., Shahab C.K. Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis. Pharmacoeconomics 2005, 23(4):333-343.
34. Wang B., Clarke M., Thomas N., Howell S., Haji Ali Afzali H., Marshall H. The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children. Pediatr Infect Dis J 2014, 33(3):316-318.
35. 6401.0 consumer price index, Australia. TABLE 11. CPI: group, sub-group and expenditure class, index numbers by capital city 2012, Australian Bureau of Statistics, Available from: http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/6401.0Sep%202012 [accessed 12.01.13].
36. Davison A.C. Bootstrap methods and their application 1997, Cambridge University Press, Cambridge.
37. Bettinger J.A., Scheifele D.W., Le Saux N., Halperin S.A., Vaudry W., Tsang R., et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J 2013, 32(1):e20-e25.
38. Barber J., Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy 2004, 9(4):197-204.
39. Basu A., Manning W.G. Issues for the next generation of health care cost analyses. Med Care 2009, 47(7 Suppl. 1):S109-S114.
40. Hospital performance: cost per casemix-adjusted separation 2013, Australian Institute of Health and Welfare, Available from: http://www.aihw.gov.au/haag10-11/hospital-performance-cost/ [accessed 16.07.13].
41. Committee for Proprietary Medicinal Products (CPMP): points to consider on adjustment for baseline covariates. Statist Med 2004, 23(5):701-709.
42. Griffiths U.K., Dieye Y., Fleming J., Hajjeh R., Edmond K. Costs of meningitis sequelae in children in Dakar, Senegal. Pediatr Infect Dis J 2012, 31(11):e189-e195.